Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-07
2006-11-07
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255060, C514S341000, C514S342000, C514S347000, C514S349000, C514S352000, C544S405000, C544S408000, C546S268700, C546S269100, C546S269700, C546S271100, C546S272700, C546S281700, C546S294000, C546S304000, C546S307000, C546S312000
Reexamination Certificate
active
07132425
ABSTRACT:
The present invention provides a compound according to formula Iwhere the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.
REFERENCES:
patent: 3431301 (1969-03-01), Focella et al.
patent: 3776917 (1973-12-01), Mann et al.
patent: 5113013 (1992-05-01), Powell et al.
patent: 5169951 (1992-12-01), Sutter et al.
patent: 5556859 (1996-09-01), Johnson
patent: 6320050 (2001-11-01), Bizzarro et al.
patent: 6353111 (2002-03-01), Corbett et al.
patent: 6369232 (2002-04-01), Sidduri
patent: 6384220 (2002-05-01), Corbett et al.
patent: 6388071 (2002-05-01), Mahaney
patent: 6388088 (2002-05-01), Sidduri
patent: 6433188 (2002-08-01), Corbett et al.
patent: 6441180 (2002-08-01), Sidduri
patent: 6441184 (2002-08-01), Corbett et al.
patent: 6448399 (2002-09-01), Corbett et al.
patent: 6486184 (2002-11-01), Kester et al.
patent: 6489485 (2002-12-01), Bizzarro et al.
patent: 6528543 (2003-03-01), Bizzarro et al.
patent: 6545155 (2003-04-01), Corbett et al.
patent: 6610846 (2003-08-01), Bizzarro et al.
patent: 249 241 (1912-07-01), None
patent: 566 138 (1993-10-01), None
patent: 1436502 (1976-05-01), None
patent: WO 00/26202 (2000-05-01), None
patent: WO 00/58293 (2000-10-01), None
patent: WO 02/08209 (2002-01-01), None
Grimsby et al, “Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy” Science, vol. 301, pp. 370-373 (Jul. 18, 2003).
Couzin, J., Comment on: Science. Jul. 18, 2003; vol. 301, pp. 370-373.
Braunstein, S. “New Developments in Type 2 Diabetes Mellitus: Combination Therapy with a Thiazolidinone” Clinical Therapeutics, vol. 23(7), pp. 1895-1917 (2003).
Colowick, S.P., The Enzymes, vol. 9 (P. Boyer, ed.) Academic Press, New York, NY, p. 1-48 (1973).
Chipkin, et. al., in Joslin's Diabetes (C.R. Kahn and G.C. Wier, eds.), Lea and Febiger, Philadelphia, PA, p. 97-115 (1994).
Printz, et. al., Ann. Rev. Nutrition, vol. 13 (R.E. Olson, D.M. Bier, and D.B. McCormick, eds.) Annual Review Inc, Palo Alto, CA pp. 463-496 (1993).
Meglasson, et. al., Amer. J. Physiol., 246, E1-E13 (1984).
Grupe, et. al., Cell 83, 69-78, (1995).
Ferre, et al., Faseb J., 10, 1213-1218 (1996).
Liang, et al., Biochem. J. 309, 167-173 (1995).
Glaser, et. al. New England J. Med. 338, 226-230 (1998).
Rodier, et. al., Acta Crystallogr., C46 (1990) pp. 154-156.
Robert, J. M. H., et al., Eur J. Med. Chem. vol. 29, (1994), pp. 841-854.
Spickett, et. al., Eur. J. Med. Chem.-Chimica Therapeutica, vol. 11(1), (1976), pp. 7-12.
Bhat, A. R., et. al., J. Inst. Chemists (India), vol. 61, 1989, pp. 134-136.
Spielman, M.A., et. al., J. Am. Chem. Soc., 70 (1948), pp. 4189-4191.
Chen Shaoqing
Corbett Wendy Lea
Guertin Kevin Richard
Haynes Nancy-Ellen
Kester Robert Francis
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Tramaloni Dennis P.
Tucker Zachary C.
LandOfFree
5-substituted-six-membered heteroaromatic glucokinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-substituted-six-membered heteroaromatic glucokinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-substituted-six-membered heteroaromatic glucokinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3670005